David C. Portnoy, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of driver mutations in the treatment of non–small cell lung cancer (NSCLC).
David C. Portnoy, MD
Advertisement
Articles by David C. Portnoy, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
3
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
4
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC
5